Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat lymphoma

NCT ID NCT04245839

Ongoing Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing an experimental cell therapy called JCAR017 for adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, specifically follicular or marginal zone lymphoma. Participants receive chemotherapy followed by a single infusion of their own genetically modified immune cells. The study aims to see how many patients respond and how long the response lasts, with follow-up for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

JCAR017 (a CAR T-cell therapy) given after lymphodepleting chemotherapy with fludarabine and cyclophosphamide

What this could lead to

If successful, this could offer a new treatment option for people with certain slow-growing lymphomas that have not responded to standard therapies.

What could go wrong

This is a mid-stage trial without a comparison group, so results are preliminary. CAR T-cell therapies can cause serious side effects like cytokine release syndrome and neurological problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm follicular lymphoma Lymphoma, B-Cell, Marginal Zone lymphoma, non-Hodgkin, familial marginal zone lymphoma non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

  • Local Institution - 100

    Boston, Massachusetts, 02114, United States

  • Local Institution - 101

    Boston, Massachusetts, 02215, United States

  • Local Institution - 102

    Baltimore, Maryland, 21201, United States

  • Local Institution - 103

    Chicago, Illinois, 60611, United States

  • Local Institution - 104

    Houston, Texas, 77030, United States

  • Local Institution - 105

    New Haven, Connecticut, 06520, United States

  • Local Institution - 107

    Aurora, Colorado, 80045, United States

  • Local Institution - 108

    Seattle, Washington, 98109, United States

  • Local Institution - 109

    Niles, Illinois, 60714, United States

  • Local Institution - 110

    Charlotte, North Carolina, 28204, United States

  • Local Institution - 111

    Santa Monica, California, 90095, United States

  • Local Institution - 112

    Cleveland, Ohio, 44195, United States

  • Local Institution - 113

    Sioux Falls, South Dakota, 57105, United States

  • Local Institution - 114

    Portland, Oregon, 97213, United States

  • Local Institution - 115

    Charlottesville, Virginia, 22903, United States

  • Local Institution - 116

    New York, New York, 10021, United States

  • Local Institution - 117

    Philadelphia, Pennsylvania, 19104, United States

  • Local Institution - 119

    Houston, Texas, 77030, United States

  • Local Institution - 121

    Dallas, Texas, 75230-2510, United States

  • Local Institution - 122

    Iowa City, Iowa, 52242, United States

  • Local Institution - 123

    Morristown, New Jersey, 07960, United States

  • Local Institution - 124

    Wichita, Kansas, 67124, United States

  • Local Institution - 127

    Detroit, Michigan, 48201, United States

  • Local Institution - 150

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 151

    Montreal, Quebec, H1T 2M4, Canada

  • Local Institution - 200

    London, NW1 2PG, United Kingdom

  • Local Institution - 201

    Manchester, M20 4BX, United Kingdom

  • Local Institution - 250

    Pierre-Bénite, 69495, France

  • Local Institution - 251

    Montpellier, 34295, France

  • Local Institution - 252

    Lille, 59037, France

  • Local Institution - 253

    Rennes, 35023, France

  • Local Institution - 254

    Toulouse, 31100, France

  • Local Institution - 255

    Paris, 75475, France

  • Local Institution - 300

    Bergamo, 24127, Italy

  • Local Institution - 301

    Naples, 80131, Italy

  • Local Institution - 350

    Salamanca, 37007, Spain

  • Local Institution - 351

    Seville, 41013, Spain

  • Local Institution - 353

    Madrid, 28007, Spain

  • Local Institution - 450

    Vienna, 1090, Austria

  • Local Institution - 500

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Local Institution - 501

    Cologne, 50937, Germany

  • Local Institution - 502

    Munich, 81377, Germany

  • Local Institution - 503

    Karlsruhe, 76135, Germany

  • Local Institution - 504

    Regensburg, Bavaria, 93053, Germany

  • Local Institution - 550

    Chuo-ku, Tokyo, 1040045, Japan

  • Local Institution - 551

    Minato-ku, Tokyo, 105-8470, Japan

  • Local Institution - 552

    Fukuoka, 812-8582, Japan

  • Local Institution - 553

    Sapporo, Hokkaido, 0608648, Japan

  • Local Institution - 600

    Stockholm, 14186, Sweden